Explore the Potential with AI-Driven Innovation
Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.
We pick out particular compounds from an extensive virtual database of more than 60 billion molecules. The preparation and shipment of these compounds are facilitated by our associate Reaxense.
In the library, a selection of top modulators is provided, each marked with 38 ADME-Tox and 32 parameters related to physicochemical properties and drug-likeness. Also, every compound comes with its best docking poses, affinity scores, and activity scores, providing a comprehensive overview.
We use our state-of-the-art dedicated workflow for designing focused libraries.
Fig. 1. The sreening workflow of Receptor.AI
Utilising molecular simulations, our approach thoroughly examines a wide array of proteins, tracking their conformational changes individually and within complexes. Ensemble virtual screening enables us to address conformational flexibility, revealing essential binding sites at functional regions and allosteric locations. Our rigorous analysis guarantees that no potential mechanism of action is overlooked, aiming to uncover new therapeutic targets and lead compounds across diverse biological functions.
Our library stands out due to several important features:
partner
Reaxense
upacc
Q9P0N5
UPID:
TM216_HUMAN
Alternative names:
-
Alternative UPACC:
Q9P0N5; A8MZ23; B7Z8N1
Background:
Transmembrane protein 216 plays a crucial role in tissue-specific ciliogenesis, essential for the proper function and structure of cilia. It is a part of the tectonic-like complex, influencing ciliary membrane composition. This protein's involvement in ciliogenesis underscores its importance in cellular and physiological processes.
Therapeutic significance:
Transmembrane protein 216 is linked to Joubert syndrome 2 and Meckel syndrome 2, diseases characterized by developmental anomalies and organ dysfunctions. Understanding the role of Transmembrane protein 216 could open doors to potential therapeutic strategies for these ciliopathies, highlighting its significance in medical research.